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Abstract 
Background: Electrical impedance technology has been well established for the last 20 years. Recently research has 
begun to emerge into its potential uses in the detection and diagnosis of pre-malignant and malignant conditions. 
The aim of this study was to systematically review the clinical application of electrical impedance technology in the 
detection of malignant neoplasms.
Methods: A search of Embase Classic, Embase and Medline databases was conducted from 1980 to 22/02/2018 to 
identify studies reporting on the use of bioimpedance technology in the detection of pre-malignant and malignant 
conditions. The ability to distinguish between tissue types was defined as the primary endpoint, and other points of 
interest were also reported.
Results: 731 articles were identified, of which 51 reported sufficient data for analysis. These studies covered 16 dif-
ferent cancer subtypes in a total of 7035 patients. As the studies took various formats, a qualitative analysis of each 
cancer subtype’s data was undertaken. All the studies were able to show differences in electrical impedance and/or 
related metrics between malignant and normal tissue.
Conclusions: Electrical impedance technology provides a novel method for the detection of malignant tissue, with 
large studies of cervical, prostate, skin and breast cancers showing encouraging results. Whilst these studies provide 
promising insights into the potential of this technology as an adjunct in screening, diagnosis and intra-operative 
margin assessment, customised development as well as multi-centre clinical trials need to be conducted before it can 
be reliably employed in the clinical detection of malignant tissue.
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Background
Over the last 30  years, oncological treatment strategies 
have been efficiently developed, researched and stream-
lined to enable rapid diagnosis and effective manage-
ment of malignant disease. More recently there has 
been particular interest into biotechnology that can 
further improve the diagnosis and surgical management 
of malignancies, especially in non-/minimally-invasive 
ways; examples include breath biomarkers of cancer, 
minimally-invasive surgical strategies such as robotic and 
transanal surgery, as well as surgical margin technolo-
gies [1–5]. Consequently, an increasing body of research 
into the clinical application of electrical impedance tech-
niques has been emerging.
Electrical impedance is a well-established physical 
concept in which an object’s impedance (a surrogate 
calculated measure of electrical conductivity) to an 
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applied alternating current over increasing frequencies 
can be measured, in order to assess tissue composition 
[6]. Whilst it has been used extensively in the engi-
neering domain, over the last 30 years there has been 
increasing interest into its use and application in the 
medical world. Resultingly this technology is now uti-
lized in everyday clinical practice in intensive care and 
nutritional medicine, in the measurement of fluid vol-
umes as well as overall fluid status and body composi-
tion [6, 7].
It is known that tissue conductivity and impedance 
changes as cell structure, fluid status and electrical 
current alters, as seen in Fig. 1 [8]. Due to this unique 
property, there has been a lot of inquiry into how elec-
trical impedance changes as tissue becomes pathologi-
cal, specifically malignant. It has been hypothesized 
that as a malignant pathological process causes trans-
formation of the cellular structure, the tissue’s electri-
cal conductivity and therefore electrical impedance 
would also change [9]. Over the recent years there has 
been renewed interest and research looking at elec-
trical impedance changes in various cancer subtypes. 
Although there is some understanding of the patho-
logical processes underlying these changes, there has 
yet to be a general consensus on how exactly tissue 
electrical impedance changes with the development of 
a malignant process [10].
Therefore, the objective of this systematic review 
was to compare the results from studies looking at 
electrical impedance changes in various cancer sub-
types, in order to assess this technology’s potential 
application in the detection of malignant neoplasms.
Methods
A qualitative systematic review was undertaken using 
the Preferred Reporting Items for Systematic Reviews 
and Meta-analysis (PRISMA) guidance. Embase Clas-
sic, Embase, Psychinfo and Medline search engines were 
used to perform a systematic literature review between 
1980 and 22/02/2018. The following search terms were 
used with the Boolean operators OR: bioimpedance, 
electrical impedance spectroscopy, electrical impedance 
tomography. These results were then searched for “cancer 
or oncology” and duplication bias studies were removed. 
The abstracts of the remaining studies were then inde-
pendently analysed (by AAP and RAW) to identify stud-
ies eligible for inclusion. Those studies that were written 
in the English language were evaluated against the fol-
lowing inclusion criteria:
• Studies of human adult tissue
• Studies where either in vivo tissue or ex vivo freshly 
resected tissue was tested
• Comparative studies evaluating electrical impedance 
of cancer against normal tissue
• Comparative studies where histopathological tissue 
diagnosis of the different tissue samples tested was 
used as the reference point.
Conference abstracts as well as general abstracts 
which had not progressed to full published articles were 
excluded. The references of those articles that met the 
inclusion criteria were then cross-referenced to ensure 
that no other studies were missed. The data from all the 
eligible studies were then computerised and collated. 
As there was considerable heterogeneity between the 
Fig. 1 Diagram showing how conduction alters with electrical and structural changes
Page 3 of 11Pathiraja et al. J Transl Med          (2020) 18:227  
various included studies, the articles that were relevant to 
the review were classified according to their cancer sub-
types, and a qualitative analysis of the data set was made, 
with the primary endpoint of the studies being defined as 
the ability to distinguish between normal and pre-malig-
nant and/or malignant tissue. Other clinically relevant 
results were also identified and reported.
For each study AUROC (area under the receiver oper-
ating characteristic curve), sensitivity and specificity 
data were collected where available. Where AUROC 
data was not available, a standard composite measure 
of sensitivity and specificity was used: Youden index, 
calculated as (sensitivity + specificity) minus 1 [11]. 
This is an established surrogate measure, representing 
the vertical distance between a putative AUROC curve 
and the equal line [11]. In order to compare the stud-
ies, the discriminative strengths were then qualitatively 
categorised as: “Good”, AUROC > 0.7 or sensitivity and 
specificity both > 0.75 or Youden index > 0.5; “Moderate”, 
AUROC > 0.6 or Sensitivity > 0.7 and Youden index > 0.25; 
“Insufficient”, not meeting the aforementioned criteria or 
reporting insufficient data. For each cancer type, a quali-
tative categorisation of the body of evidence was made, 
based on the discriminative strength of each study as well 
as the size and number of studies.
Results
From 731 abstracts identified, 73 articles met the inclu-
sion criteria, of which 51 had sufficient data that could 
be analysed. Figure  2 shows the PRISMA flowchart 
employed for this review.
51 articles covering the study of electrical impedance 
spectroscopy (EIS) on 16 different malignant tissue types 
were analysed. These covered a total of 7035 patients’ 
specimens analysed by EIS in 16 different cancer types 
(compared with corresponding normal tissue). 29 studies 
were published after 2010, and 10 of these were published 
in 2015 or after. All 4 cutaneous melanoma studies, 1 
breast study and 1 hepatic study were conducted as mul-
ticentre studies; all other studies (45)   were conducted 
at single sites. All 4 cervical studies, both tongue studies 
and all except 1 of the 12 prostate studies were conducted 
at the same institution. 23 of the studies were conducted 
in the USA and 15 in Europe.
Table  1 describes the outcomes of in  vivo studies 
reporting on pre-malignant and malignant tissue states. 
Table 2 shows the results of all the other studies investi-
gating impedance in malignant tissue types only. Table 3 
provides summative results of all 51 studies by cancer 
type, and a Additional file 1: Table S1 details key second-
ary outcomes for all the studies analysed in the review.
Fig. 2 PRISMA flow chart of study selection
Page 4 of 11Pathiraja et al. J Transl Med          (2020) 18:227 
Cancer subtypes
Breast cancer
Twelve articles described studies into breast cancer on 
a total of 2460 patients. Six of the 12 studies looked at 
in vivo tissue by measuring the electrical impedance and 
electrical properties of the overlying skin or lesion itself 
intra-operatively [12–17], whilst the other six studies 
directly measured impedance of fresh ex vivo specimens 
[18–23]. Three studies looked at intra-ductal carcinoma 
(IDC) alone [12, 13, 20], whilst six studies looked at vari-
ous different carcinoma subtypes [14–17, 21, 22], and 
the remaining three studies did not report the exact his-
topathology of the cancer specimens tested [14, 19, 21]. 
All the studies noted statistically significant changes in 
various electrical impedance metrics of malignant tissue, 
and 2 of the studies went on to use the metrics to form a 
classification by which they were able to accurately dis-
criminate tissue based on the classification results [19, 
23]. One study was able to integrate the various param-
eters  (Ro/R∝ and  fc) to create a new parameter that was 
able to distinguish malignant tissue with an AUROC of 
0.93 [24]. Four of the breast studies used EIS technology 
either integrated or in combination with mammographic 
technology in order to produce images as well as quan-
titative measurements of the tissue [13, 15–17]. One 
study was able to show that impedance was affected by 
age and hormonal state of the patient and was most sen-
sitive at identifying cancers in patients under 40 without 
any palpable lesions [22]. In addition to the quantitative 
results reported in Table 2, most of the studies also con-
cluded that as the technology was found to be painless, 
non-invasive and radiation-free, it had the potential to be 
developed into a useful pre-screening tool.
Prostate cancer
Twelve articles looked at changes in electrical imped-
ance related to prostate cancer on a total of 297 patients, 
with only two of the studies examining in vivo tissue [24, 
25]. Of the two in vivo studies, one applied an ultrasound 
probe that had integrated electrical impedance technol-
ogy, so that measures could be taken from the probe 
prior to surgical excision of the tissue [24]. The second 
in  vivo study measured whole body electrical imped-
ance and chronoamperometry in patients with and with-
out cancer, in order to determine impedance differences 
between the 2 groups, as well as improved detection 
rates when combining electrical impedance measures 
with PSA levels [25]. Additionally, the two in vivo studies 
used EIS devices that were able to produce images that 
could identify malignant lesions. All 12 studies showed 
statistically significant differences in impedance metrics 
between normal and malignant prostatic tissue, and 1 
study was also able to discriminate between low-grade 
and high-grade malignant tissue as well [26]. One study 
showed that different histopathologies produced differ-
ent EIS spectra, as well as statistically significant differ-
ences in tissue resistivity between malignant and benign 
prostatic hypertrophic tissue [27]. 11 of the studies were 
Table 1 Results of in vivo studies of pre-malignant and malignant tissue
AUROC: area under receiver operating characteristic curve for discrimination between neoplasia and normal tissue; CIN: cervical intraepithelial neoplasia; NMSC: non-
melanomatous skin cancer; Melanoma refers to cutaneous melanoma in all cases. SCC: squamous cell carcinoma; NR: not reported
a Discriminative strength is a summary of the reported quantitative indices for discrimination between neoplastic and normal tissue in each study, not taking into 
account the number of samples. This was rated as follows: “Good”, AUROC > 0.7 or sensitivity and specificity both > 0.75 or Youden index > 0.5; “Moderate”, AUROC > 0.6 
or Sensitivity > 0.7 and Youden index > 0.25; “Insufficient”, not meeting the above criteria or insufficient data. Youden index is calculated as the (sensitivity + specificity) 
minus 1 [11]
Author Country Histology 
of pre-/
malignant 
tissue
No. of pre-/
malignant 
samples
No. of normal 
(control) 
samples
AUROC Sensitivity (%) Specificity (%) Discriminative 
 strengtha
Tidy 2013 UK High-grade CIN 87 109 0.827 86 56 Good
Balasubramani 
2009
UK High-grade CIN 85 681 0.800 79 73 Good
Brown 2000 UK High-grade CIN 126 370 0.951 92 92 Good
Abdul 2006 UK High-grade CIN 178 680 0.652 74 53 Moderate
Malvehy 2014 Multi-centre Melanoma, 
NMSC
320 320 NR 97 34 Moderate
Mohr 2013 Multi-centre Melanoma, 
NMSC
126 126 NR 98 NR Insufficient
Aberg 2011 Multi-centre Melanoma 59 59 0.850 95 49 Good
Rocha 2017 Multi-centre Melanoma 6 154 NR 100 70 Good
Murdoch 2014 UK Oral SCC 10 61 0.776 65 92 Good
Sarode 2015 India Oral SCC 50 50 NR NR NR Insufficient
Page 5 of 11Pathiraja et al. J Transl Med          (2020) 18:227  
Table 2 Results of other studies comparing malignant neoplasm versus normal tissue (grouped by cancer type)
IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; DCIS: ductal carcinoma in situ; LCIS: lobular carcinoma in situ; SCC: squamous cell carcinoma; BCC: 
basal cell carcinoma; (Various): more than 3 histological cancer subtypes included; ‘–’, not stated
a Discriminative strength is a summary of the reported quantitative indices for discrimination between neoplastic and normal tissue in each study, not taking into 
account the number of samples. This was rated as follows: “Good”, AUROC > 0.7 or sensitivity and specificity both > 0.75 or Youden index > 0.5; “Moderate”, AUROC > 0.6 
or Sensitivity > 0.7 + Youden index > 0.25; “Insufficient”, not meeting the above criteria or insufficient data. Youden index is calculated as (sensitivity + specificity) minus 
1 [11]
b This study reported moderate discriminative ability in the < 40 year group
c These two studies reported statistically significant differences between malignant and normal tissue on EIS, but insufficient data for calculating the overall 
discriminative strength
Author Country of origin Site Histology of malignant 
tissue tested
Cancer 
samples
Benign samples Specimen state Discriminative 
 strengtha
Halter 2015 USA Breast IDC 10 9 In-vivo Good
Gregory 2012 USA Breast IDC or ILC ± DCIS or LCIS 232 141 Ex-vivo Insufficient
Kim 2007 USA Breast IDC 1 1 In-vivo Insufficient
Cherepenin 2001 Russia Breast – 21 21 In-vivo Insufficient
da Silva 2000 Portugal Breast – 21 42 Ex-vivo Insufficient
Osterman 2000 USA Breast ILC or IDC 3 12 In-vivo Insufficient
Chauveau 1999 France Breast IDC 2 1 Ex-vivo Insufficient
Jossinet 1998 France Breast – 23 64 Ex-vivo Insufficient
Stojadinovic 2005 Multicentre Breast (Various) 29 1074 Ex-vivo Good
Kao 2008 USA Breast IDC and DCIS 3 1 In-vivo Moderateb
Halter 2009 USA Breast IDC + DCIS 11 4 Both Insufficient
Du 2017 China Breast (Various) 581 395 Ex-vivo Good
Mahara 2015 USA Prostate – 3 3 Ex-vivo Insufficient
Mishra 2013 USA Prostate – 21 367 Ex-vivo Good
Wan 2013 USA Prostate – 45 45 In-vivo Insufficient
Mishra 2012 USA Prostate – 36 288 Ex-vivo Insufficient
de Abreu 2011 Brazil Prostate – 23 27 In-vivo Insufficient
Halter 2011 USA Prostate – 71 465 Ex-vivo Good
Halter 2008 USA Prostate – 29 151 Ex-vivo Insufficient
Halter 2007 USA Prostate Adenocarcinoma o 5 Ex-vivo Insufficient
Khan 2016 USA Prostate – 23 53 Ex-vivo Insufficient
Murphy 2017 USA Prostate – 12 105 Ex-vivo Good
Lee 1999 USA Prostate – 6 6 Ex-vivo Insufficient
Halter 2008 USA Prostate – 17 345 Ex-vivo Insufficient
Keshtkar 2006 Iran Bladder – 24 73 In-vivo Insufficient
Wilkinson 2002 UK Bladder – 35 35 Ex-vivo Insufficient
Keshtkar 2012 Iran Bladder – 30 100 Ex-vivo Good
Prakash 2014 USA Hepatic Metastasis-colorectal primary 41 91 Ex-vivo Insufficient
Laufer 2010 Israel & USA Hepatic – 32 26 Ex-vivo Insufficient
Gao 2014 China Lung (Various) 91 91 Ex-vivo Insufficient
Cherepenin 2001 Russia Lung – 22 7 In-vivo Insufficient
Sun 2010 Taiwan Tongue SCC 12 12 In-vivo Insufficientc
Ching 2010 Taiwan Tongue SCC 5 5 In-vivo Insufficient
Dua 2004 USA Skin -BCC BCC 18 16 In-vivo Insufficient
Kuzmina 2005 Sweden Skin -BCC BCC 35 35 In-vivo Insufficient
Keshtkar 2012 Iran Gastric Adenocarcinoma 19 22 In-vivo Insufficient
Yun 2016 South Korea Renal RCC 10 10 Ex-vivo Insufficient
Zheng 2013 USA Thyroid Papillary & follicular 27 133 In-vivo Good
Pathiraja 2017 UK Colorectal Adenocarcinoma 22 22 Ex-vivo Good
Habibi 2011 USA Skin-scc SCC 1 14 In-vivo Insufficient
Knabe 2013 Germany Oesophagus Adenocarcinoma & SCC 30 19 In-vivo Insufficientc
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conducted at the same institution, employing similar 
tools and methodology, in which the electrical imped-
ance measurement was integrated into the prostate 
biopsy device [24, 26–34]. Three of the studies report on 
optimal frequencies noted for discrimination of tissue; 
however, all the frequencies reported were found to be 
different. All 11 studies from the same institution found 
that the electrical impedance was significantly higher in 
prostate cancer tissue compared to normal prostatic tis-
sue. The results from the prostate studies suggest that 
such technology could be developed to provide a real-
time screening tool and even an adjunct to PSA testing in 
prostate cancer screening programmes.
Cervical cancer
Four large in  vivo studies looked at electrical imped-
ance changes found at colposcopy of suspicious cervical 
lesions on a total of 638 patients. All these studies were 
conducted at the same centre, using the same tools and 
methodology [10, 35–37]. All four studies showed that 
electrical impedance measurements were able to reliably 
discriminate high-grade cervical intra-epithelial neo-
plasm (CIN) from normal cervical tissue, with AUROC 
ranging from 0.652–0.951. The accuracy of detection of 
pre-malignant lesions was relatively unaffected by the 
application of acetic acid to the tissue (which is routinely 
done during colposcopic assessment of suspicious cervi-
cal lesions) and was generally found to be very sensitive 
but less specific in lesion identification [36]. All 4 studies 
suggest that as the CIN grade increases, the impedance 
and resistivity decrease whilst conductivity increases. 
The studies also found that combining EIS measurement 
with colposcopy increases the accuracy of the detection 
of high-grade CIN [35]. Further statistical analysis of the 
results from all 4 studies showed the following weighted 
means: AUROC of 0.8, sensitivity of 0.81, and specificity 
of 0.71.
Skin cancer
4 large-scale multicentre trials involving 2933 patients 
looked at electrical impedance changes found in cuta-
neous melanomas. All the trials were conducted in vivo, 
using a similar methodology [38–41]. All the studies 
showed the electrical impedance technology was able to 
distinguish both melanomatous and non-melanomatous 
skin tumours with very high sensitivities > 95%. They 
also noted that the sensitivity of the technique increased 
further as the Breslow thickness of the malignant tissue 
increased. All the studies were also able to identify statis-
tically significant differences between normal tissue, non-
malignant atypical lesions and non-melanomatous skin 
cancers. Additionally, 1 study was able to combine der-
moscopy results with a higher EIS cut-off level to identify 
malignant lesions with 100% sensitivity [38].
Oral cancer
Four studies looked at two types of oral lesions: two stud-
ies tested in vivo oral SCC lesions in 198 patients [42, 43], 
Table 3 Summative results of the 51 studies by cancer type
SCC: squamous cell carcinoma; NMSC: non-melanomatous skin cancer; BCC: basal cell carcinoma; ‘–’, not stated
Summative evidence strength classified as “Strong”: 2 or more large studies with good discriminative ability
“Moderate”: good discriminative indices described but in small numbers for any specific histological type
“Weak”: insufficient statistical data to demonstrate significant discriminative ability currently
Site of malignancy Histopathological type No. of studies Total no. 
of patients
Specimen state Summative evidence
Cervical Cervical SCC 4 638 In-vivo Stronga
Prostate – 12 297 Both Strong
Skin Skin melanoma & NMSC 7 3009 In-vivo Moderate
Breast Various carcinomas 12 2460 Both Moderate
Oral mucosa SCC 2 198 In-vivo Moderate
Bladder – 3 123 Both Moderate
Thyroid Various carcinomas 1 27 In-vivo Moderate
Colorectal Adenocarcinoma 1 22 Ex-vivo Moderate
Tongue SCC 2 29 In-vivo Weak
Lung Various 2 138 Both Weak
Hepatic Metastases 2 16 Ex-vivo Weak
Oesophagus SCC & adenocarcinoma 1 23 In-vivo Weak
Gastric Adenocarcinoma 1 45 In-vivo Weak
Renal Renal cell carcinoma 1 10 Ex-vivo Weak
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and two tested in vivo SCCs occurring on the tongue in 
29 patients, both of which were conducted at the same 
institution [44, 45]. All four studies reported that oral 
and tongue SCCs had much lower impedance measures 
than normal oral and tongue epithelium respectively 
and could therefore be identified. Both studies of tongue 
cancer as well as one of the oral SCC studies showed sta-
tistically significant differences in impedance were most 
pronounced between 20  Hz and 50  kHz [43–45]. The 
two studies of tongue cancers also showed differences in 
other impedance metrics between normal and malignant 
tongue lesions.
Bladder cancer
3 studies looked at electrical impedance changes in blad-
der malignancy of 123 patients [46–48], of which one 
study was an in vivo investigation [46]. All three studies 
found that malignant urothelium had higher electrical 
impedance than normal urothelium, and one study was 
able to record an AUROC of 0.887, showing good sepa-
ration between normal and malignant tissue [48]. Addi-
tionally, one of the studies noted important effects of 
oedema and inflammation on the impedance results [47]. 
All three studies suggest that following further develop-
ment of the customised technology, electrical impedance 
could play a role in assisting in cystoscopic assessment 
and screening of suspicious urothelial lesions.
Hepatic cancer
Two studies looked at the electrical impedance of ex vivo 
hepatic malignancies in 16 patients; one of the studies 
focussed on primary malignancy [49] whilst the other 
study looked at hepatic metastasis from a colonic pri-
mary cancer [50]. Both studies showed that the malignant 
tissue exhibited a much higher conductivity than the nor-
mal tissue, and consequently a much lower impedance 
than normal tissue. One of the studies highlighted the 
importance of malignant tissue’s higher conductivity in 
relation to radiofrequency (RF) ablation of hepatic tissue: 
lowering RF ablation frequencies may enable better tar-
geting of the malignant tissue alone, without surrounding 
normal tissue conducting and consequently being dam-
aged by RF ablation [49].
Lung cancer
Two articles looked at lung malignancies of various path-
ological subtype in 138 patients. Both studies were able 
to show that various measured electrical impedance met-
rics were able to discriminate lung cancer from normal 
healthy lung tissue [51, 52]. In particular lung cancer 
showed a statistically significant increase in conductiv-
ity compared to normal tissue. One study goes further by 
suggesting that its method of static electric impedance 
tomography could potentially be developed into a screen-
ing tool for lung cancer [52].
Basal cell carcinoma
Two articles looked at electrical impedance changes in 
in  vivo basal cell carcinomatous tissue on a total of 61 
patients. In both studies various EIS parameters could 
accurately distinguish BCC from normal tissue with sta-
tistical significance, as well as consistently lower imped-
ance measurements in BCCs compared to normal tissue 
[53, 54]. One study compared measuring the lesion’s 
impedance along with its surrounding skin, against the 
lesion alone, and was able to show 100% vs. 85% sensi-
tivity respectively [53]. The second study additionally 
looked at laser Doppler and transepidermal water loss 
measurements as well as impedance measures and found 
similar trends between all 3 sets of measurements, but 
was unable to discriminate between the nodular- and 
superficial subtype of the lesion [54].
Individual studies of other cancers
Six other independent studies looked at the effects of 
the malignant process on the electrical conductivity of 
various tissue types, four of which were on in vivo speci-
mens. The 6 individual tissue types included thyroid 
malignancies, squamous cell carcinomas of the skin, 
oesophageal adenocarcinoma and squamous cell carci-
noma, gastric adenocarcinoma, colorectal adenocarci-
noma and renal cell carcinoma [55–60]. Whilst these six 
individual studies were generally of a smaller malignant 
tissue sample size, all six studies were able to show that 
various bioimpedance parameters could be used to dis-
tinguish malignant from normal tissue. The studies of 
gastric adenocarcinoma, renal cell carcinomas, various 
thyroid malignancies and squamous cell skin cancer all 
showed malignant tissue to have lower impedance and/
or resistivity/permittivity than normal [55–58], whilst 
the colorectal and oesophageal studies showed higher 
impedance with malignant lesions compared to normal 
[58–60]. Additionally, the colorectal study showed that 
in two previously malignant lesions that had shown com-
plete response to chemoradiotherapy, the impedance 
measurements appeared to be similar to that of normal 
colorectal tissue [58].
Two cancer groups’ evidence—cervical and prostate 
cancer—were categorised as “strong”, having two or more 
large studies with strong discriminative variables, good 
reference standards and homogenous methodologies 
between studies. Six cancer types were deemed to have 
“moderate” evidence; these included skin, breast, oral, 
bladder, thyroid and colorectal cancer. Although there 
were multiple studies on various breast, skin and oral 
cancers, only two studies on breast cancer, two studies 
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on melanoma, and one study on oral cancer showed good 
discriminative ability [12, 23, 40–42]. The studies on 
bladder, thyroid and colorectal cancer showed promising 
early results in terms of discriminative indices, but had 
small sample sizes [46–48, 57, 58]. The 6 remaining can-
cer types—tongue, lung, hepatic metastasis, oesophageal, 
gastric and renal—were categorised as having “weak” evi-
dence as the studies reported insufficient data: either not 
enough quantitative data, or other metrics that could not 
be quantified.
Discussion
The aim of this study was to evaluate the clinical appli-
cation of electrical impedance technology in the detec-
tion of malignant neoplasms. A systematic review of the 
available published data over the last 36 years identified 
51 articles that studied the effect of malignancy on tissue 
electrical impedance and its associated metrics, which 
have been reported in this paper.
All the studies reported differences in electrical imped-
ance and/or related metrics between the normal tissue 
and corresponding malignant tissue. However, the actual 
change in the impedance itself appeared to vary depend-
ing on the histopathological cancer that was measured. 
As the electrical impedance spectroscopy and tomog-
raphy technology generates various metrics including 
conductivity, resistivity, and impedance/admittivity, as 
well as tomographic spatial images, various changes 
in these different metrics were noted. It was noted that 
the majority of the squamous cell carcinomatous tis-
sue seemed to result in significantly lower impedance 
spectra, in contrast with the adenocarcinomatous tissue 
studies, which gave a more variable spread of impedance 
changes. This finding was consistently seen throughout 
all the studies of cervical, skin and oral squamous cell 
carcinomas (SCC), where the SCC tissue gave signifi-
cantly lower SCC readings than its corresponding nor-
mal tissue. Conversely, adenocarcinomatous tissue types 
seen in the prostate, breast, oesophageal and colorectal 
studies showed more variable results. Whilst the breast 
and oesophageal studies showed lower impedance levels 
in the adenocarcinomatous subtypes of tissue examined, 
the prostate and colorectal studies showed significantly 
higher electrical impedance levels in the malignant tis-
sue. Additionally, the colorectal study showed that in a 
small subset of specimens that had undergone complete 
response to chemoradiotherapy, the resulting impedance 
appeared to have returned to a lower impedance, similar 
to that of normal colorectal tissue. It is unclear as to why 
these differences occur. However, as none of the studies 
look at the individual histopathological states on a micro-
scopic level, correlation between the cellular changes and 
impedance changes could not be established at this stage. 
Additionally, as the studies on the adenocarcinomatous 
tissues were of a much smaller magnitude than the much 
larger-scale cervical and cutaneous melanoma studies, 
it is difficult to make firm conclusions based on these 
results alone.
In the studies of both cervical tissue and cutaneous 
skin lesions, the electrical impedance technology was so 
sensitive that it was able to discriminate between normal 
and pre-malignant tissue as well as normal and malig-
nant tissue, with AUROC analysis of over 95% and 85% 
respectively. These findings are particularly significant 
as the cervical and cutaneous data sets represent a very 
large sample size of 638 and 2933 patients respectively. 
Additionally, the cutaneous lesion data sets originate 
from four separate multi-centre trials, which all showed 
similar trends in very high sensitivities, with compara-
tively lower specificities. As these large-scale studies have 
shown such significant results, they strongly suggest the 
potential diagnostic accuracy of real-time diagnosis of 
cervical CIN and malignant skin lesions, using electrical 
impedance technology.
Another interesting point to note was that several dif-
ferent studies exploited the EIS technology in order to 
tailor the parameters measured and/or the ergonomics 
of the tool for the specific cancer in question. One study 
in the breast cancer subgroup had specifically designed 
their EIS algorithms to be most accurate for breast tis-
sue of women under 40, whilst another study in the pros-
tate subgroup integrated the EIS technology onto the 
end of an endoanal ultrasound probe in order to access 
and measure the field of interest. Additionally, several 
research groups in breast and prostate used the technol-
ogy to produce real-time images (“maps”) that correlated 
directly with the anatomy being measured. These studies 
show the great potential of this technology, not only in 
the way that the EIS metrics can be specifically tailored 
and displayed, but also in the breadth of application of 
this compact, mobile and cheap electrode technology in 
various clinically appropriate forms.
One major limitation that should be noted in this 
review is that several of the studies (25/51) included in 
this systematic review used ex vivo specimens; only the 
cervical, cutaneous and oral lesion studies exclusively 
looked at electrical impedance on in pre-/malignant 
and normal tissue. One of the breast studies included a 
comparison between in  vivo and ex  vivo measurements 
of specimens and showed that various EIS metrics (con-
ductivity and permittivity) clearly decrease as measure-
ments are taken ex vivo. It is known that as soon as tissue 
is resected and loses its blood supply, the fluid status of 
the tissue changes, which in turn would affect the elec-
trical conductivity and impedance properties of the tis-
sue. However, it is understandable that in these initial 
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proof-of-concept studies where novel technology and 
techniques are being used for the first time, ex vivo stud-
ies precede more realistic in  vivo studies. Therefore, 
further research examining the electrical impedance of 
these tissue types in  vivo would be required before an 
assessment of the effectiveness of this technology could 
be made.
Another limitation to consider is that many of the 
studies included have a small sample size, and have each 
reported on different outcomes, which therefore could 
not be statistically analysed as a whole. This heterogene-
ity is increased by the studies having multiple variables, 
such as frequency ranges applied by the studies’ tools, 
the specific impedance tool used as well as unreported 
ischaemic times. For the cancer types that have many 
studies reporting findings, the studies have often been 
conducted at the same institution using the same meth-
odology but have not reported quantitative statistics 
that could be pooled for analysis. Consequently, more 
meaningful statistical analysis of the results could not 
be reported at this early stage. Nevertheless, qualitative 
analysis of the results was still possible, from which sig-
nificant conclusions and further work can be planned.
Conclusions
This is the first systematic review into the application of 
electrical impedance technology on normal, pre-malig-
nant and malignant tissue types. Although the studies are 
mostly heterogeneous in their methodologies and find-
ings, they do provide evidence of the technical feasibil-
ity of electrical impedance technology for differentiating 
between normal, pre-malignant and malignant lesions 
in a range of tissue types. This has the potential to be 
exploited as a diagnostic adjunct, for example as dem-
onstrated by the use of EIS in colposcopy for the assess-
ment of cervical abnormalities; in the latter case though 
research into long-term outcomes is recommended and 
remains to be seen [61]. Additionally, in the context of 
endoscopic, robotic and artificial intelligence technology, 
electrical impedance has the potential to be integrated 
into these technologies to further augment their capabili-
ties [62, 63].
Further histopathological analysis needs to occur along-
side analysis of the impedance data, in order to fully under-
stand why these changes are occurring. Through better 
understanding of the underlying malignant structural dif-
ferences causing the changes in electrical impedance, this 
technology could be specifically enhanced both technically 
and ergonomically, in order to examine these changes more 
accurately. In order for this technology to be more rigor-
ously assessed in the future, large-scale multicentre in vivo 
studies will be needed, in order to calculate the optimal 
tools and metrics that give the most accurate rates of cancer 
detection. Additionally, the effects that these technologies’ 
results have on clinical decision-makers’ behaviours as well 
as the patients’ long-term outcomes will need to be investi-
gated in future studies. If this novel technology can be fur-
ther developed and found to improve detection rates and 
surgical outcomes, these highly sensitive and non-invasive 
real-time diagnostic tools could be implemented through-
out various different clinical settings (ranging from bed-
side diagnosis to intra-operative margin assessment), and 
thereby provide point-of-care testing, real-time diagnosis 
and effective surgical management of the patient’s cancer in 
an efficient and cost-effective manner.
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